{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:26:17Z","timestamp":1774437977540,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T00:00:00Z","timestamp":1317168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00198-011-1773-0","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T20:24:36Z","timestamp":1317155076000},"page":"1747-1756","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study"],"prefix":"10.1007","volume":"23","author":[{"given":"P. D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Riis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Masanauskaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kenwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Stakkestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,28]]},"reference":[{"key":"1773_CR1","unstructured":"National Institutes of Health 2000 Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement Online March 27\u201329 17:1\u201336. http:\/\/consensus.nih.gov\/2000\/2000Osteoporosis111html.htm . Accessed 10 March 2010"},{"key":"1773_CR2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s001980170017","volume":"12","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, Papadimitropoulos EA, Hopman W, Poliquin S, Prior JC, Hanley DA, Olszynski WP, Anastassiades T, Brown JP, Murray T, Jackson SA, Tenenhouse A, Canadian Multicentre Osteoporosis Study (CaMos) Research Group (2001) The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12:903\u2013908","journal-title":"Osteoporos Int"},{"key":"1773_CR3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1503\/cmaj.080709","volume":"181","author":"P Rahmani","year":"2009","unstructured":"Rahmani P, Morin S (2009) Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ 181:815\u2013820","journal-title":"CMAJ"},{"key":"1773_CR4","first-page":"1293","volume":"70","author":"TM Zizic","year":"2004","unstructured":"Zizic TM (2004) Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 70:1293\u20131300","journal-title":"Am Fam Physician"},{"key":"1773_CR5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1773_CR6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1773_CR7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1773_CR8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. J Am Med Assoc 282:1344\u20131352","journal-title":"J Am Med Assoc"},{"key":"1773_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J-Y Reginster","year":"2000","unstructured":"Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1773_CR10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00198-003-1571-4","volume":"15","author":"PN Sambrook","year":"2004","unstructured":"Sambrook PN, Rodriguez JP, Wasnich RD, Luckey MM, Kaur A, Meng L, Lombardi A (2004) Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 15:483\u2013488","journal-title":"Osteoporos Int"},{"key":"1773_CR11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"1773_CR12","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1773_CR13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"1773_CR14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstrom","year":"2004","unstructured":"Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u2013468","journal-title":"Calcif Tissue Int"},{"key":"1773_CR15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","volume":"21","author":"CH Chesnut","year":"2005","unstructured":"Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 21:391\u2013401","journal-title":"Curr Med Res Opin"},{"key":"1773_CR16","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"1773_CR17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1\u00a0year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"1773_CR18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1773_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","volume":"85","author":"R Wasnich","year":"2000","unstructured":"Wasnich R, Miller P (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin End Metab 85:231\u2013246","journal-title":"J Clin End Metab"},{"key":"1773_CR20","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","volume":"87","author":"M Hochberg","year":"2002","unstructured":"Hochberg M, Greenspan S, Wasnich R (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin End Metab 87:1586\u20131592","journal-title":"J Clin End Metab"},{"key":"1773_CR21","first-page":"1","volume":"843","author":"World Health Organization","year":"1994","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1\u2013129","journal-title":"World Health Organ Tech Rep Ser"},{"key":"1773_CR22","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. http:\/\/www.ema.europa.eu\/pdfs\/human\/ewp\/55295enfin.pdf . Accessed 4 May 2010"},{"key":"1773_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/ciia.2006.1.4.415","volume":"1","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415\u2013423","journal-title":"Clin Interv Aging"},{"key":"1773_CR24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96\u2013110","journal-title":"Hormones (Athens)"},{"key":"1773_CR25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","volume":"3","author":"O Bock","year":"2008","unstructured":"Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis\u2014optimizing efficacy in clinical practice. Clin Interv Aging 3:279\u2013297","journal-title":"Clin Interv Aging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1773-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1773-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1773-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:41Z","timestamp":1558609721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1773-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,28]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1773-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,28]]}}}